NICE does not recommend Saxenda as a treatment for obesity. - Novo Nordisk

The National Institute for Health and Care Excellence (NICE) has rejected Saxenda ( liraglutide) from Novo Nordisk for use on the NHS, citing its list price and lack of long-term efficacy data in recently published draft guidance . Saxenda showed clinical effectiveness in preventing the development of Type 2 diabetes but NICE argued that "its long-term effectiveness, particularly on the risk of cardiovascular disease, is unknown." NICE was also not impressed with Saxenda's price—listed at £196.20 ($256.43) for 5 x 6 mg/ml 3-ml (18 mg) pre-filled pens—despite a confidential discount from Novo.